



## EXTRAORDINARY INFORMATION

Egis Pharmaceuticals PLC (Egis) informs its business partners that, in line with AstraZeneca's request, the court added Egis as a defendant in the patent litigation between plaintiff AstraZeneca and defendant Watson Laboratories, Inc. (Watson) that is pending in the state of Delaware, USA.

The original case against Watson arose from Watson's filing of a New Drug Application seeking FDA approval to market a rosuvastatin zinc product developed and manufactured by Egis to compete with AstraZeneca's Crestor® product in the United States. According to the data published by IMS Health, the USA turnover of Crestor® was 4.1 billion USD in the 12-month period ending on 30 September 2011.

The aim of the litigation is to decide whether the marketing of such rosuvastatin zinc product can be started in the USA without the infringement of various patents relating to rosuvastatin. The claims against Egis arise from Egis' commercial relationship with the Watson group regarding the rosuvastatin zinc product for which Watson seeks approval.

Egis will vigorously defend the claims against it and further informs its business partners that the complaint does not seek a monetary damage award against Egis.

At the present phase of the case Egis cannot provide substantive information on the timing of the commercial launch and on the expected sales revenue.

### About Watson

Watson Pharmaceuticals Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.

### About Egis

The Budapest-based Hungarian Egis Pharmaceuticals Public Limited Company is one of the leading regional generic pharmaceutical companies the operational focus of which is Central Europe, Russia and the CIS countries. Its scope of activity focuses on the development, manufacture and marketing of finished pharmaceuticals and active pharmaceutical ingredients suitable for treatment of cardiovascular diseases, disorders of the central nervous system, the respiratory and digestive systems. Three quarters of its sales revenue comes from export. As far as the size of its research and development expenditures Egis takes the third place among all industrial companies of the Central European region.

Crestor® is the trademark of the AstraZeneca group of companies.

Budapest, March 26, 2012

Egis Pharmaceuticals PLC